Eagle and Mystic lead AstraZeneca’s cancer clear out, with MedImmune name also retired by Nick Paul Taylor Thursday, February 14, 2019 The PD-L1 combination trials led the clear out, and the immuno-oncology drugs tested in those studies feature heavily in the earlier-phase cull.
Exoduses continue at AstraZeneca—Chutes & Ladders by Conor Hale Friday, January 18, 2019 CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs.
Sean Bohen to leave AstraZeneca as exodus continues by Ben Adams Monday, January 14, 2019 Bloomberg reports that Sean Bohen, CMO and EVP of global medicines development, is out the door at AstraZeneca.
Baselga to helm AstraZeneca’s cancer R&D—Chutes & Ladders by Conor Hale Friday, January 11, 2019 Baselga to helm AstraZeneca’s cancer R&D; ex-Novartis exec joins UroGen; Roche exec moves to Genevant; and Immunocore poaches from AZ’s biologics arm.
Baselga takes helm of AstraZeneca’s cancer R&D by Ben Adams Monday, January 7, 2019 Major changes are afoot at AstraZeneca as it shakes up its research structure with new units, new names and big moves.
Immunocore digs into AstraZeneca’s biologics arm for new CEO by Ben Adams Monday, January 7, 2019 Nearly a year after its former chief Eliot Forster stepped down, Immunocore has a new full-time CEO in Medimmune’s president Bahija Jallal.
Guardant to develop blood tests for AstraZeneca’s targeted drugs by Conor Hale Friday, December 14, 2018 AstraZeneca has tapped Guardant Health to develop blood-based companion diagnostics for its cancer treatments Tagrisso and Imfinzi.
AstraZeneca, Cancer Research UK debut functional genomics center by Joseph Keenan Thursday, December 13, 2018 AstraZeneca is partnering with Cancer Research UK to debut a new research facility that will focus on using CRISPR and other functional genomics tech.
